Alliancebernstein L.P. decreased its stake in Integra LifeSciences Holdings Corporation (NASDAQ:IART) by 6.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 94,516 shares of the life sciences company’s stock after selling 6,300 shares during the period. Alliancebernstein L.P. owned about 0.12% of Integra LifeSciences Holdings Corporation worth $5,152,000 at the end of the most recent quarter.

Several other large investors also recently modified their holdings of the company. Eagle Asset Management Inc. raised its position in shares of Integra LifeSciences Holdings Corporation by 39.0% during the 2nd quarter. Eagle Asset Management Inc. now owns 1,647,018 shares of the life sciences company’s stock valued at $89,778,000 after buying an additional 461,977 shares in the last quarter. Koch Industries Inc. bought a new stake in shares of Integra LifeSciences Holdings Corporation during the 1st quarter worth $250,000. Schwab Charles Investment Management Inc. lifted its holdings in shares of Integra LifeSciences Holdings Corporation by 116.8% during the 1st quarter. Schwab Charles Investment Management Inc. now owns 244,982 shares of the life sciences company’s stock worth $10,322,000 after acquiring an additional 131,995 shares during the last quarter. Strs Ohio lifted its holdings in shares of Integra LifeSciences Holdings Corporation by 60.4% during the 2nd quarter. Strs Ohio now owns 7,700 shares of the life sciences company’s stock worth $419,000 after acquiring an additional 2,900 shares during the last quarter. Finally, Jennison Associates LLC lifted its holdings in shares of Integra LifeSciences Holdings Corporation by 12.3% during the 2nd quarter. Jennison Associates LLC now owns 697,772 shares of the life sciences company’s stock worth $38,036,000 after acquiring an additional 76,548 shares during the last quarter. 84.90% of the stock is currently owned by hedge funds and other institutional investors.

Several brokerages recently issued reports on IART. Oppenheimer Holdings, Inc. set a $60.00 target price on shares of Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research report on Saturday, June 24th. UBS AG restated a “buy” rating and set a $60.00 price target (up previously from $48.00) on shares of Integra LifeSciences Holdings Corporation in a research report on Friday, June 9th. Raymond James Financial, Inc. raised their price target on Integra LifeSciences Holdings Corporation from $51.00 to $55.00 and gave the company an “outperform” rating in a research report on Thursday, July 27th. Zacks Investment Research lowered Integra LifeSciences Holdings Corporation from a “hold” rating to a “sell” rating in a research note on Wednesday, June 28th. Finally, Cantor Fitzgerald set a $65.00 price target on Integra LifeSciences Holdings Corporation and gave the stock a “buy” rating in a research note on Wednesday, July 26th. Five equities research analysts have rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $53.64.

In other Integra LifeSciences Holdings Corporation news, Director Barbara B. Hill purchased 5,050 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Tuesday, August 1st. The shares were bought at an average price of $49.33 per share, for a total transaction of $249,116.50. Following the completion of the transaction, the director now owns 44,772 shares of the company’s stock, valued at approximately $2,208,602.76. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Donald E. Morel, Jr. purchased 2,500 shares of Integra LifeSciences Holdings Corporation stock in a transaction that occurred on Thursday, August 3rd. The stock was acquired at an average price of $49.29 per share, for a total transaction of $123,225.00. Following the transaction, the director now directly owns 29,612 shares of the company’s stock, valued at approximately $1,459,575.48. The disclosure for this purchase can be found here. Insiders have bought a total of 17,550 shares of company stock worth $864,842 over the last ninety days. Insiders own 21.50% of the company’s stock.

Integra LifeSciences Holdings Corporation (IART) opened at 50.48 on Monday. Integra LifeSciences Holdings Corporation has a 52 week low of $37.71 and a 52 week high of $56.42. The stock’s 50 day moving average price is $50.51 and its 200-day moving average price is $48.58. The company has a market capitalization of $3.94 billion, a PE ratio of 61.56 and a beta of 0.72.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) last released its quarterly earnings data on Wednesday, July 26th. The life sciences company reported $0.45 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.45. Integra LifeSciences Holdings Corporation had a return on equity of 16.79% and a net margin of 6.27%. The business had revenue of $282.16 million for the quarter, compared to the consensus estimate of $283.58 million. During the same quarter in the previous year, the company posted $0.40 EPS. The company’s revenue was up 13.2% compared to the same quarter last year. On average, equities research analysts predict that Integra LifeSciences Holdings Corporation will post $1.90 earnings per share for the current fiscal year.

WARNING: This story was reported by Watch List News and is owned by of Watch List News. If you are reading this story on another website, it was copied illegally and reposted in violation of US and international copyright & trademark legislation. The original version of this story can be accessed at https://www.watchlistnews.com/integra-lifesciences-holdings-corporation-iart-shares-sold-by-alliancebernstein-l-p/1602384.html.

About Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including product portfolio used in the neurosurgery operating suite and critical care unit, and Orthopedics and Tissue Technologies, which includes differentiated soft tissue repair and tissue regeneration products, and small bone fixation and joint replacement solutions.

Institutional Ownership by Quarter for Integra LifeSciences Holdings Corporation (NASDAQ:IART)

Receive News & Ratings for Integra LifeSciences Holdings Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences Holdings Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.